{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:38:48Z","timestamp":1787881128125,"version":"build-2784847793"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The aim of this large, prospective, double-blind randomized controlled trial is to investigate the effect of atorvastatin on the formation of collateral blood vessels in patients after encephaloduroarteriosynangiosis (EDAS) and to provide a theoretical basis for clinical drug intervention. Specifically, we will determine whether atorvastatin has an effect on the development of collateral vascularization and on cerebral blood perfusion after revasculoplasty in patients with moyamoya disease (MMD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>Overall, 180 patients with moyamoya disease will be recruited and randomly assigned to the atorvastatin treatment group or the placebo control group in a 1:1 ratio. Before revascularization surgery, magnetic resonance imaging (MRI) scanning and digital subangiography (DSA) examination will be routinely performed on the enrolled patients. All patients will receive intervention via EDAS. According to the randomization results, patients in the experimental group will be treated with atorvastatin (20\u2009mg\/day, once a day, for 8 weeks) and patients in the control group will be treated with placebo (20\u2009mg\/day, once a day, for 8 weeks). All participants will return to the hospital for MRI scan and DSA examination 6 months after EDAS surgery. The primary outcome of this trial will be the difference in the formation of collateral blood vessels revealed by DSA examination at 6 months after EDAS surgery between the two groups. The secondary outcome will be an improvement in the dynamic susceptibility contrast sequence cerebral perfusion on MRI at 6 months after EDAS, compared to the preoperative baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>This study was approved by the Ethics Committee of the First Medical Center of the PLA General Hospital. All participates will voluntary provide written informed consent before participating in the trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, ChiCTR2200064976.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1169253","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:20:14Z","timestamp":1685593214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["To explore the effectiveness of atorvastatin in the postoperative formation of collateral blood vessels after encephaloduroarteriosynangiosis in patients with moyamoya disease: a prospective double-blind randomized controlled study"],"prefix":"10.3389","volume":"14","author":[{"given":"Gan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian-Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Bin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/s0303-8467(97)00033-4","article-title":"Natural history of Moyamoya disease: comparison of activity of daily living in surgery and non surgery groups","volume":"99","author":"Choi","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archneur.1969.00480090076012","article-title":"Cerebrovascular \u201cmoyamoya\u201d disease. Disease showing abnormal net-like vessels in base of brain","volume":"20","author":"Suzuki","year":"1969","journal-title":"Arch Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2176\/nmc.52.245","article-title":"Guidelines for diagnosis and treatment of Moyamoya disease (spontaneous occlusion of the circle of Willis)","volume":"52","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3171\/2018.2.PEDS17591","article-title":"Encephaloduroarteriosynangiosis for pediatric Moyamoya disease: long-term follow-up of 100 cases at a single center","volume":"22","author":"Zhang","year":"2018","journal-title":"J Neurosurg Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/j.wneu.2018.04.076","article-title":"Long-term outcomes after encephaloduroarteriosynangiosis in adult patients with Moyamoya disease presenting with ischemia","volume":"115","author":"Bao","year":"2018","journal-title":"World Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12975-020-00834-9","article-title":"Endothelial progenitor cells induce angiogenesis: a potential mechanism underlying neovascularization in encephaloduroarteriosynangiosis","volume":"12","author":"Wang","year":"2021","journal-title":"Transl Stroke Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease","volume":"103","author":"Vasa","year":"2001","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","article-title":"Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans","volume":"111","author":"Landmesser","year":"2005","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.3171\/2021.6.FOCUS21112","article-title":"The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial","volume":"51","author":"Wang","year":"2021","journal-title":"Neurosurg Focus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2176\/jns-nmc.2021-0382","article-title":"2021 Japanese guidelines for the management of Moyamoya disease: guidelines from the research committee on Moyamoya disease and Japan stroke society","volume":"62","author":"FUJIMURA","year":"2022","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jamaneurol.2018.2030","article-title":"Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized ClinicalTrial","volume":"75","author":"Jiang","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0009-9236(96)90218-0","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects","volume":"60","author":"Cilla","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s0090-3019(81)80017-1","article-title":"A new surgical treatment of Moyamoya disease in children: a preliminary report","volume":"15","author":"Matsushima","year":"1981","journal-title":"Surg Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.neurad.2016.12.006","article-title":"Clinical assessment of cerebral hemodynamics in Moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: a comparative study","volume":"44","author":"Qiao","year":"2017","journal-title":"J Neuroradiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/01.str.19.4.512","article-title":"The Dutch T1A trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke","volume":"19","year":"1988","journal-title":"Stroke"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(22)00165-X","article-title":"Moyamoya disease: diagnosis and interventions","volume":"21","author":"Ihara","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"861184","DOI":"10.3389\/fneur.2022.861184","article-title":"The potential mechanism behind native and therapeutic collaterals in moyamoya","volume":"13","author":"Bao","year":"2022","journal-title":"Front Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/0003319713507333","article-title":"Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease","volume":"65","author":"Kurtoglu","year":"2014","journal-title":"Angiology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1111\/bph.13285","article-title":"Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia","volume":"172","author":"Potey","year":"2015","journal-title":"Br J Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11481-016-9706-5","article-title":"Atorvastatin modulates regulatory T cells and attenuates cerebral damage in a model of transient middle cerebral artery occlusion in rats","volume":"12","author":"Rodr\u00edguez-Perea","year":"2017","journal-title":"J NeuroImmune Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/STROKEAHA.107.490946","article-title":"Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke","volume":"39","author":"Chen","year":"2008","journal-title":"Stroke"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1169253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:20:17Z","timestamp":1685593217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1169253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":23,"alternative-id":["10.3389\/fneur.2023.1169253"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1169253","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"article-number":"1169253"}}